Chronic Urticaria on Woman With Toxoplasmosis Post Spiramycin Treatment: A Rare Case
DOI:
https://doi.org/10.66344/jpad.v33i3.2274Keywords:
Chronic urticaria, toxoplasmosis, spiramycin, macrolideAbstract
Spiramycin is a macrolide antibiotic with a bacteriostatic action and is used as a toxoplasmosis treatment since the FDA considers it safe and can be taken throughout early pregnancy. As the therapeutic use of spiramycin increases, reports of hypersensitivity responses, characterized as urticaria, are also on the rise. A 27-year-old woman presented to the hospital with chief complaints of recurrent rash with redness and severe itch on her entire body for one week. The rash appeared after the patient was diagnosed with toxoplasmosis and instructed to take spiramycin regularly. Two months ago, the patient experienced the same complaints. The patient was diagnosed with spiramycin-induced chronic urticaria and administered dexamethasone, diphenhydramine, and fexofenadine orally. Clinical improvement is evident after three days of treatment, as evidenced by a weekly decrease in the UAS-7 score. Urticaria is a hypersensitivity reaction that can be triggered by antibiotic consumption. A comprehensive diagnosis is needed to determine the etiology of urticaria, including the history of drug consumption. Treatment of urticaria includes education and the administration of antihistamines and corticosteroids. Chronic urticaria requires special treatment from a dermato-venerologist.
References
1. Wertenteil S, Strunk A, Garg A. Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysis. J Am Acad Dermatol. 2019;81(1):152–6.
2. Chung WH, Chu CY, Huang YH, Wang WM, Yang CH, Tsai TF. Taiwanese Dermatological Association consensus for the definition, classification, diagnosis, and management of urticaria. J Formosan Med Assoc. 2016;115(11):968–80.
3. Zuberbier T, Maurer M. Urticaria: Current opinions about etiology, diagnosis, and therapy. Acta Derm Venereol. 2007;87(3):196–205.
4. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–66.
5. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. Zuberbier T, Grattan CEH, Maurer M, editors. J Allerg Clin Immunol. 2014;133(5):1270-1277.e66.
6. Kang MJ, Kim HS, Kim HO, Park YM. The Impact of Chronic Idiopathic Urticaria on Quality of Life in Korean Patients. Ann Dermatol. 2009;21(3):226.
7. Tan EK, Grattan CE. Drug-induced urticaria. Expert Opin Drug Saf. 2004;3(5):471–84.
8. Vacek V. Spiramycin. Cas Lek Cesk. 1994;133(2):56–60.
9. CDC A. Parasites-toxoplasmosis (Toxoplasma infection). Am J Trop Med Hyg. 2014;9(1):794–9.
10. Deganich M, Boudreaux C, Benmerzouga I. Toxoplasmosis Infection during Pregnancy. Trop Med Infect Dis. 2022;8(1):3.
11. Ünal D, Demir S, Gelincik A, Olgaç M, Coşkun R, Çolakoğlu B, et al. Diagnostic Value of Oral Challenge Testing in the Diagnosis of Macrolide Hypersensitivity. J Allergy Clin Immunol Pract. 2018;6(2):521–7.
12. JM L. A Case Report on Cetirizine Induced Urticaria. Clin Dermatol Open Access J. 2018;3(2).
13. Tadros S, Bahal S, Nagendran V. Case Report: Resolution of chronic urticaria following treatment of odontogenic infection. F1000Res. 2019;7:1738.
14. Seitz CS, Bröcker EB, Trautmann A. Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: Results of allergological testing. Allergol Immunopathol (Madr). 2011;39(4):193–9.
15. Araujo L, Demoly P. Macrolides Allergy. Curr Pharm Des. 2008;14(27):2840–62.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Astrid Amanda Wahyu Putri, Muhammad Edel Dwiputra Prawira, Harastha Qinthara Mathilda, Faradiani Rasyidi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
